118th Congress · HOUSE BILLBILL

H.R. 4408Promising Pathway Act

To amend the Federal Food, Drug, and Cosmetic Act to establish a time-limited provisional approval pathway, subject to specific obligations, for certain drugs and biological products, and for other purposes.

Health
Introduced Jun 30, 2023
Last action Jul 7, 2023
Pipeline · Bill → Law
Step 1
Introduced
Jun 30, 2023
Step 2
Referred
Jul 7, 2023
E&C
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary

This bill provides for expedited, provisional approval of drugs for serious or life-threatening diseases or conditions. Specifically, the bill allows for provisional approval of drugs that are used to treat, prevent, or diagnose a serious or life-threatening disease or condition for which premature death is likely without early medical intervention. The Food and Drug Administration (FDA) must evaluate applications within 90 days of receipt. The FDA may approve applications if there is early evidence, including real-world and real-time evidence, of the drug's efficacy, as well as substantial evidence of the drug's safety. Provisional approval is valid for two years and may be renewed for up...

Provisions · 2 sectionsIntroduced in House
Timeline · 3 actions
Jul 7, 2023
Referred to the Subcommittee on Health.
Jun 30, 2023
Introduced in House
Jun 30, 2023
Referred to the House Committee on Energy and Commerce.